221
Views
14
CrossRef citations to date
0
Altmetric
Research Article

Folate-decorated and NIR-activated nanoparticles based on platinum(IV) prodrugs for targeted therapy of ovarian cancer

, , , , &
Pages 675-686 | Received 17 Jun 2017, Accepted 12 Oct 2017, Published online: 16 Nov 2017
 

Abstract

Platinum-based drugs are used to treat a variety of cancers but have many side effects such as nephrotoxicity and neurotoxicity. A folate-decorated nanoparticles system with a good drug payload can selectively deliver drugs into folate receptor (FR)-overexpressing cancer cells to prevent the shortcomings of platinum-based chemotherapy. Here, folate-decorated and near-infrared (NIR) laser-activated nanoparticles (abbreviated as PtIV-FINPs) were prepared via ultrasonic self-assembling of platinum(IV) prodrug c,c,t-Pt(NH3)2Cl2(OOCCH2CH2COOH)2, folic acid (FA)-functionalized lipid DSPE-PEG-FA and NIR fluorescent dye indocyanine green (ICG). The obtained PtIV-FINPs had almost spherical shape with a mean diameter about 100 nm. In vitro cellular uptake, cytotoxicity assays revealed that upon NIR irradiation, PtIV-FINPs further enhanced cellular uptake and generated higher cytotoxicity against human ovarian carcinoma SKOV3 cells than non-targeted or non-NIR activated nanoparticles. Thus, the multifunctional nanoparticles have potential to be developed as an attractive drug delivery system for effective chemotherapy against FR-overexpressing cells.

Disclosure statement

The authors report no conflicts of interest.

Additional information

Funding

This work was supported by National Natural Science Foundation of China [No. 21371031], Anhui Provincial Natural Science Foundation [No. 1708085MH207], International S&T Cooperation Program of China [No. 2015DFG42240], Engineering Technology Research Center of Polysaccharides Drug of Anhui Province, Priority Academic Program Development of Jiangsu Higher Education Institutions.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.